Replies to post #44796 on Ariad Pharmaceuticals Inc fka ARIA

[ilpapa]

Earnings per share?

What company are you babbling about?

[AmpleKind]

Rather scathing: "The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself."

Boilerplate! This exact wording is pasted into every reference Cramer's
minions make to Ariad. BTW, it's nonsense on the face of it (no relevance to
Ariad's situation whatsoever).

Rather irrelevant!